指南与共识眼底病与葡萄膜炎

COVID-19疫情期间非感染性葡萄膜炎免疫调节治疗的共识演变

Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic.
指南 / 共识 · Br J Ophthalmol · 2020-06-25

本研究通过横断面调查139名国际葡萄膜炎专家,围绕COVID-19疫情期间非感染性葡萄膜炎患者免疫调节治疗的启动、继续、减量和停止等临床问题形成共识声明。最高共识为:对疑似或确诊COVID-19患者不启动免疫调节治疗,对重症或致死性COVID-19高风险和极高风险患者优先使用局部而非全身皮质类固醇治疗。

要点

  • 疑似或确诊COVID-19的非感染性葡萄膜炎患者不启动免疫调节治疗获得最高共识。
  • 重症或致死性COVID-19高风险和极高风险患者优先使用局部而非全身皮质类固醇。
  • 健康患者巩膜炎可启动NSAIDs治疗获共识,任何风险组均未就启动羟氯喹达成共识。

核心结论

  • 基于全球专家意见和实践经验形成共识指南,以弥合临床需求与医学证据缺乏之间的差距,指导COVID-19疫情期间非感染性葡萄膜炎患者的治疗。

研究设计与样本

  • 横断面调查国际葡萄膜炎专家,由专家指导委员会确定临床问题,139名全球葡萄膜炎专家通过交互式在线问卷形成共识声明。

主要发现

  • 最高共识为对疑似或确诊COVID-19患者不启动免疫调节治疗。
  • 对重症或致死性COVID-19高风险和极高风险患者使用局部而非全身皮质类固醇治疗达成共识。
  • 健康患者巩膜炎治疗启动NSAIDs达成共识。
  • 任何风险组启动羟氯喹均未达成共识。

关键数值与推荐

  • 疑似或确诊COVID-19患者不启动免疫调节治疗(最高共识)。
  • 重症或致死性COVID-19高风险和极高风险患者优先使用局部而非全身皮质类固醇治疗(共识)。
  • 健康患者巩膜炎可启动NSAIDs治疗(共识)。
  • 任何风险组启动羟氯喹均无共识。

临床怎么用

  • COVID-19疫情期间,对疑似或确诊COVID-19的非感染性葡萄膜炎患者应避免启动免疫调节治疗。
  • 对重症或致死性COVID-19高风险和极高风险患者,优先选择局部而非全身皮质类固醇治疗。
  • 健康巩膜炎患者可考虑启动NSAIDs治疗,但不建议在任何风险组启动羟氯喹。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunomodulatory therapy (IMT) is often considered for systemic treatment of non-infectious uveitis (NIU). During the evolving coronavirus disease-2019 (COVID-19) pandemic, given the concerns related to IMT and the increased risk of infections, an urgent need for guidance on the management of IMT in patients with uveitis has emerged. METHODS: A cross-sectional survey of international uveitis experts was conducted. An expert steering committee identified clinical questions on the use of IMT in patients with NIU during the COVID-19 pandemic. Using an interactive online questionnaire, guided by background experience and knowledge, 139 global uveitis experts generated consensus statements for IMT. In total, 216 statements were developed around when to initiate, continue, decrease and stop systemic and local corticosteroids, conventional immunosuppressive agents and biologics in patients with NIU. Thirty-one additional questions were added, related to general recommendations, including the use of non-steroidal anti-inflammatory drugs (NSAIDs) and hydroxychloroquine. RESULTS: Highest consensus was achieved for not initiating IMT in patients who have suspected or confirmed COVID-19, and for using local over systemic corticosteroid therapy in patients who are at high-risk and very high-risk for severe or fatal COVID-19. While there was a consensus in starting or initiating NSAIDs for the treatment of scleritis in healthy patients, there was no consensus in starting hydroxychloroquine in any risk groups. CONCLUSION: Consensus guidelines were proposed based on global expert opinion and practical experience to bridge the gap between clinical needs and the absence of medical evidence, to guide the treatment of patients with NIU during the COVID-19 pandemic.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Agrawal R, Testi I, Lee CS, et al. Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic. Br J Ophthalmol. 2020. PMID: 32586933. doi:10.1136/bjophthalmol-2020-316776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。